BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance

Supplemental material placed on this supplemental material which has been supplied by the author(s) Pract Neurol

First line immunosuppression in

neuromuscular disease:
Initiation checklist Patient details:

Diagnosis:
Definite Probable Possible

Evidence-based therapy: Y N

Patient information booklet provided: Y N

Informed consent Y N
• Discussed alternatives Y N
• Drug-specific risks discussed Y N

General risk assessment:

• Baseline bloods Y N
o Normal Y N
• TB: low risk High risk/ treatment required
• Flu/ pneumococcal vaccinations: Y N
• Baseline
o Lung disease: Y N
o Liver disease Y N
o Renal impairment Y N
• HIV, HBV, HVC checked Y N
• Cardiovascular risk: Y N
o Primary prevention Y N
• PJP prophylaxis required Y N
• Bone protection required Y N
o FRAX Y N
o Vit D/ Calcium screen Y N
• Pregnant Y N
o Contraception advice Y N

Drug specific monitoring

• As per guideline Y N
o Normal Y N

Outcome measures and baseline measurements:

Date:
1.
2.
3.
4.

Foster MA, et al. Pract Neurol 2023;0:1–14. doi: 10.1136/pn-2023-003708